South Carolina Doc Loses License Over Bad Prescriptions
Published Date: 9/30/2025
Notice
Summary
Dr. Henry Emery lost his permission to handle controlled substances in South Carolina and North Carolina because he no longer has legal authority in those states and allegedly prescribed drugs improperly. The DEA officially revoked his registrations after he didn’t respond to their orders. This means Dr. Emery can’t legally prescribe or handle controlled substances in these states anymore, effective immediately.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
DEA Registrations Revoked in SC and NC
The Drug Enforcement Administration revoked Henry Emery, M.D.'s DEA registrations No. FE7195452 (South Carolina) and No. BE7654127 (North Carolina), effective October 30, 2025. Because his South Carolina medical license was suspended on March 14, 2024, and he entered an Interim Non‑Practice Agreement in North Carolina on December 27, 2023, he cannot legally prescribe or handle controlled substances in those two states, and the DEA denied any pending or future renewal, modification, or additional registration applications in South Carolina or North Carolina.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-19057 — Self-Regulatory Organizations; 24X National Exchange LLC; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Amend the Limited Liability Agreement of 24X US Holdings LLC Regarding the Warrant Performance Incentive Program
24X National Exchange is updating its parent company’s agreement to tweak the Warrant Performance Incentive Program, which rewards certain company achievements. This change affects 24X US Holdings LLC and kicks in right away, aiming to keep incentives clear and fair without impacting money flow immediately. If you’re involved with 24X, this update is your new playbook for how performance rewards work.
Next: 2025-19059 — Self-Regulatory Organizations; National Securities Clearing Corporation; Notice of Designation of Longer Period for Commission Action on Proposed Rule Change To Amend the CNS Fails Charge in the NSCC Rules
The National Securities Clearing Corporation (NSCC) wants to change the rules about fees charged when members don’t settle trades on time. The Securities and Exchange Commission (SEC) is taking extra time to review this proposal, pushing the decision deadline from October 31 to a later date. This affects financial firms that use NSCC’s services and could impact how much they pay if they miss settlement deadlines.